‘It Kills Me to Say That': Cramer Won't Recommend Pfizer, Even With Its 7% Dividend

Pfizer’s Q1 2026 results posted a revenue beat ($14.45B vs $13.80B estimate) and a fifth straight adjusted EPS beat ($0.75), but Cramer remains cautious because the growth outlook is still unclear despite a ~7% trailing yield. Management reaffirmed FY2026 guidance of $59.5B–$62.5B revenue and adjusted EPS of $2.80–$3.00, yet revenue and operating income pressures persist (net income -9.44% YoY; operating income -31.44%). The dividend is framed as safe at the 7% level (raised $0.42 to $0.43 starting Jan 2026), while ongoing investment/deal activity (including the ~ $7.0B Metsera deal) has not yet translated into renewed earnings growth.

Analysis

The setup is less about the dividend itself and more about whether capital allocation can outrun the post-COVID earnings air pocket. A 7% yield is only supportive if the payout is not crowding out reinvestment; here, the market is effectively saying the cash return is being used as a substitute for a visible growth bridge, which caps the multiple despite low headline valuation. That tends to keep the stock in a narrow range until management proves that M&A or pipeline assets can add to EPS within 4-6 quarters, not 4-6 years.

Second-order, the weakness is a relative-value gift to higher-quality pharma and biotech. If Pfizer remains a capital return story without near-term growth, capital should migrate toward names with cleaner self-funding pipelines and better operating leverage, especially large-cap defensives with visible launches and stronger pricing power. The real competitive risk is not just lost share in legacy products, but the opportunity cost of being absent from the parts of pharma where the market is still willing to pay growth multiples.

The contrarian view is that the downside may already be largely known: the stock is being priced like a bond proxy with equity optionality, so absent a negative surprise, the yield can attract a floor from income mandates. What would change the tape is evidence that one of the newer deals meaningfully shifts 2027–2028 consensus EPS, or a management action that converts cash flow into share count reduction instead of more pipeline spending. Near term, the stock likely trades on yield and guidance credibility; over 6-18 months, it trades on whether the pipeline can stop being a story and start being a number.

Key Decisions for Investors

• Use PFE as a relative-value short against better-growth defensives: long ABBV or MRK / short PFE for a 3- to 6-month pair, targeting multiple compression in PFE if it continues to trade as a yield trap; thesis fails if PFE raises 2026 EPS guide or announces accretive pipeline data.
• Avoid initiating fresh outright longs in PFE until there is proof of earnings inflection; if already long for income, consider trimming into rallies and treating the name as a cash-yield position, not a growth compounder.
• For income investors who must own pharma, rotate from PFE into higher-quality dividend growers with visible catalysts rather than chasing yield alone; PFE only belongs in the basket if the goal is dividend capture, not total return.
• Watch for a catalyst window around the next earnings/strategy update and any obesity/oncology readout; if the market does not re-rate on that event, consider a tactical short into the post-event drift.
• Set a risk alert if PFE breaks materially below the 52-week low or if forward EPS estimates are cut again; that would signal the market is no longer willing to underwrite the dividend floor without growth, increasing downside air pocket risk.